BRIEF-Tiziana Life Sciences Announces Positive Results From Ozempic And Nasal Anti-CD3 Combination Study

Reuters10-30

Oct 30 (Reuters) - Novo Nordisk A/S :

* TIZIANA LIFE SCIENCES ANNOUNCES POSITIVE RESULTS FROM OZEMPIC AND NASAL ANTI-CD3 COMBINATION STUDY

* TIZIANA LIFE SCIENCES LTD - COMBINATION OF NASAL ANTI-CD3 AND SEMAGLUTIDE IMPROVES LIVER HOMEOSTASIS

* TIZIANA LIFE SCIENCES LTD - COMBINATION SIGNIFICANTLY REDUCES INFLAMMATION MARKERS IN OBESITY-RELATED DISORDERS

Source text: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2479200688?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-30 21:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2479200688","market":"us","top_or_hot":-1,"title":"BRIEF-Tiziana Life Sciences Announces Positive Results From Ozempic And Nasal Anti-CD3 Combination Study","media":"Reuters","content":"<html><body><p>Oct 30 (Reuters) - Novo Nordisk A/S   :</p><p>   * TIZIANA LIFE SCIENCES ANNOUNCES POSITIVE RESULTS FROM OZEMPIC AND NASAL ANTI-CD3 COMBINATION STUDY</p><p>   * TIZIANA LIFE SCIENCES LTD - COMBINATION OF NASAL ANTI-CD3 AND SEMAGLUTIDE IMPROVES LIVER HOMEOSTASIS</p><p>   * TIZIANA LIFE SCIENCES LTD - COMBINATION SIGNIFICANTLY REDUCES INFLAMMATION MARKERS IN OBESITY-RELATED DISORDERS</p><p>Source text:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Tiziana Life Sciences Announces Positive Results From Ozempic And Nasal Anti-CD3 Combination Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Tiziana Life Sciences Announces Positive Results From Ozempic And Nasal Anti-CD3 Combination Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-30 21:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Oct 30 (Reuters) - Novo Nordisk A/S   :   * TIZIANA LIFE SCIENCES ANNOUNCES POSITIVE RESULTS FROM OZEMPIC AND NASAL ANTI-CD3 COMBINATION STUDY   * TIZIANA LIFE SCIENCES LTD - COMBINATION OF NASAL ANTI...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TLSA","symbol_name":"Tiziana Life Sciences PLC","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2479200688","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2479200688","pubTimestamp":1730294048,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Oct 30  - Novo Nordisk A/S   :   * TIZIANA LIFE SCIENCES ANNOUNCES POSITIVE RESULTS FROM OZEMPIC AND NASAL ANTI-CD3 COMBINATION STUDY   * TIZIANA LIFE SCIENCES LTD - COMBINATION OF NASAL ANTI-CD3 AND SEMAGLUTIDE IMPROVES LIVER HOMEOSTASIS   * TIZIANA LIFE SCIENCES LTD - COMBINATION SIGNIFICANTLY REDUCES INFLAMMATION MARKERS IN OBESITY-RELATED DISORDERSSource text:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TLSA":"Tiziana Life Sciences PLC","BK4139":"生物科技"},"translate_title":"BRIEF-Tiziana Life Sciences宣布Ozempic和鼻腔抗CD3联合研究的积极结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TLSA":0.9},"content_text":"Oct 30 (Reuters) - Novo Nordisk A/S   :   * TIZIANA LIFE SCIENCES ANNOUNCES POSITIVE RESULTS FROM OZEMPIC AND NASAL ANTI-CD3 COMBINATION STUDY   * TIZIANA LIFE SCIENCES LTD - COMBINATION OF NASAL ANTI-CD3 AND SEMAGLUTIDE IMPROVES LIVER HOMEOSTASIS   * TIZIANA LIFE SCIENCES LTD - COMBINATION SIGNIFICANTLY REDUCES INFLAMMATION MARKERS IN OBESITY-RELATED DISORDERSSource text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2479200688"}